

Supplementary Table 2. Patients and tumor molecular characteristics as a function of the presence of *F nucleatum* subspecies in colorectal cancer tissues.

F nucleatum subspecies animalis

Characteristic	<i>ssp animalis</i> -negative	<i>ssp animalis</i> -positive	OR (95% CI)*	OR (95% CI)**
Age at diagnosis +				
Mean	63.3	62.9		
N	1735	116		
Sex				
Male	870 (50)	46 (40)	Ref	Ref
Female	866 (50)	70 (60)	1.52 (1.04-2.25, p-val = 0.0313)	1.35 (0.91 - 2.02, p-val = 0.13)
sample size	1736	116		
Cancer stage				
stage I	482 (35)	15 (19)	Ref	Ref
stage II	375 (27)	28 (35)	2.30 (1.21-4.53, p-val = 0.013)	2.20 (1.12 - 4.44, p-val = 0.024)
stage III	362 (26)	31 (39)	2.55 (1.35-5.01, p-val = 0.005)	2.67 (1.38 - 5.38, p-val = 0.0041)
stage IV	150 (11)	6 (8)	1.25 (0.43-3.11, p-val = 0.65)	1.56 (0.53 - 4.13, p-val = 0.39)
N	1369	80		
Tumor site				
rectal	434 (25)	16 (13.7)	Ref	Ref
distal	559 (32)	25 (21.6)	1.19 (0.63-2.31, p-val = 0.59)	1.12 (0.59-2.18, p-val = 0.72)
proximal	743 (43)	75 (65.7)	2.75 (1.61-4.96, p-val = 0.00039)	1.76 (0.99-3.29, p-val = 0.065)
left (rectal + distal)	993 (57.2)	41 (35.1)	Ref	Ref
right	743 (42.8)	75 (64.7)	2.47 (1.67-3.71, p-val = 8.2e-06)	1.64(1.05-2.57, p-val = 0.029)
N	1736	116		
Hypermutation status				
non-hypermutated	1455 (84)	77 (66)	Ref	Ref
hypermutated	281 (16)	39 (34)	2.59 (1.70-3.89, p-val = 5.76e-06)	0.51 (0.24-1.1, p-val = 0.07)
N	1736	116		
Microsatellites instability status				
MSS	1495 (86)	73 (63)	Ref	Ref
MSI	241 (14)	43 (37)	2.84 (1.81-4.43, p-val = 4.86e-06)	3.81 (1.84-7.71, p-val = 0.00025)
N	1736	116		

F nucleatum subspecies vincentii and nucleatum

Characteristic	other <i>ssp</i> (not <i>animalis</i>)-negative	other <i>ssp</i> (not <i>animalis</i>)-positive	OR (95% CI)*	OR (95% CI)***
Age at diagnosis+				
Mean	63.3	65.5		
sample size	1809	42		
Sex				
Male	899 (50)	17 (40)	Ref	Ref
Female	911 (50)	25 (60)	1.46 (0.79-2.77, p-val = 0.23)	1.40 (0.75-2.67, p-val = 0.30)
N	1810	42		
Cancer stage				
stage I	486 (34)	11 (30)	Ref	Ref
stage II	390 (28)	13 (35)	1.75 (0.76-4.15, p-val = 0.19)	2.0 (0.84 - 4.96, p-val = 0.12)
stage III	385 (27)	8 (22)	1.13 (0.42-2.91, p-val = 0.81)	1.20 (0.44 -3.17, p-val = 0.72)
stage IV	151 (11)	5 (14)	1.82 (0.56-5.23, p-val = 0.28)	2.1 (0.62 - 6.2, p-val = 0.20)
N	1412	37		
Tumor site				
rectal	441 (24.4)	9 (21.4)	Ref	Ref
distal	569 (31.4)	15 (35.7)	1.26 (0.55-3.02, p-val = 0.59)	1.26 (0.55-3.04, p-val = 0.60)
proximal	800 (44.2)	18 (42.9)	1.0 (0.45-2.36, p-val = 0.99)	0.78 (0.32-1.93, p-val = 0.56)
left (rectal + distal)	1010 (55.8)	24 (57.1)	Ref	Ref
right (proximal)	800 (44.2)	18 (42.9)	0.87 (0.46-1.62, p-val = 0.66)	0.67 (0.32-1.33, p-val = 0.26)
N	1810	42		
Hypermutation status				
non-hypermutated	1498 (82.8)	34 (81)	Ref	Ref
hypermutated	312 (17.2)	8 (19)	1.03 (0.44-2.16, p-val = 0.942)	0.27 (0.08 - 0.97, p-val = 0.043)
N	1810	42		
Microsatellites instability status**				
MSS	1536 (85)	32 (76)	Ref	Ref
MSI	274 (15)	10 (24)	1.84 (0.79-4.08, p-val = 0.14)	3.81 (1.13-11.27, p-val = 0.022)
N	1810	42		

(+)To compare age at diagnosis, analysis of variance was performed (for *F nucleatum subspecies animalis* p-value = 0.71, and for *F nucleatum subspecies vincentii* and *nucleatum* p-value = 0.25); *Adjusted for age and sex; **Adjusted for age at diagnosis, sex, tumor site, hyper mutation status, MSI status and mutations in *POLE*, *TP53* and *ERBB3* (for models investigating hypermutation and MSI status, those variables were only included once in the model);

***Adjusted for age, sex, tumor site, hyper mutation status, MSI; OR = Odd Ratio; CI = Confidence Interval